×

A Double-Blind, Randomized, Parallel Placebo-Controlled phase III Study to Evaluate the Safety and Antiviral Activity of L-FMAU 30mg QD in patients with Chronic Hepatitis B. (2003.08-2004.08)
A Double-Blind, Randomized, Parallel Placebo-Controlled phase III Study to Evaluate the Safety and Antiviral Activity of L-FMAU 30mg QD in patients with HBe Ag Negative Chronic Hepatitis B. (2003.08-2004.08)
A Randomized, Double Blind Trial of LdT (Telbivudine) versus Lamivudine, in Adults with compensated Chronic Hepatitis B (2003.12-2006.12)
An open-Label, Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine in Patients who received Clevudine in L-FMAU-301, 302. (2004.08-2005.11)
A Randomized, Double Blind Trial of LdT (Telbivudine) versus Adefovir Dipivoxil, in Adults with compensated Chronic Hepatitis B (2004.10-2005.12)
Dose-ranging study of Remofovir in patients with compensated hepatitis B (2004-2005)
An open label study of adefovir dipivoxil(ADF104070) for the treatment of patients with chronic hepatitis B (CHB) related advanced fibrosis or cirrhosis. (2005-2008)
An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies (2005-2008)
A phased 3, randomized, Multi-Center Study to Evaluate the efficacy and safety of Albumin Interferon Alfa-2b in combination with Rivabirine Compared with Peginterferon Alfa-2a in Combination with Rivabirine in Interferon Alfa Naive Subjects with chronic hepatitis C Genotype 2 or 3. (2007 ? 2009)
Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytophenic subjects with hepatitis C virus(HCV) infection who are otherwise eligible to initiate antiviral therapy(peginterferon alfa-2b plus ribavirin)(2008.05-2009.6)
A Phase II-a, Open-Label, Randomized Study of JX-594(thymidine Kinase-deleted Vaccinia Virus plus GM-CSF) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma(2008.12-2009.6)
Antiviral effect, safety and pharmacokinetics of once daily BI201335NA in hepatitis C virus genotype 1 infected treatment-naive and treatment-experienced patients for 24 weeks as combination therapy with pegylated interferon-alpha 2a and ribavirin(double-blind, randomized, placebo-controlled, Phase II)(2009.3-present)
Acomparative Study of Entecavir vs Adefovir plus Lamivudine-Resistant Chronic Hepatitis B subjects: The DEFINE Study(2008. 7- present)
A Double-blind Randomized Clinical trial Comparing the Safety and antiviral activity of 48-week Clevudine and Adefovir in HBeAg(-) Chronic Hepatitis B with compensated liver function (2009.3-present)
A phase IIb, open, multinational, multi-center, randomised, comparative, parallel study to assess the safety and antiviral activity of LB80380 90 mg or 150 mg tablet compared to Entecavir 0.5 mg in chronic hepatitis B patients for 48 weeks with a planned analysis of efficacy and safety at Week 24 of the treatment for selecting optimal dose(2009.07- present)
A randomized, open label, phaseⅣ, multicenter study for efficacy and safety of lamivudine versus entecarvir therapy in HBV-related advanced liver diseasepatients with high viral load and normal or slightly elevated transaminase(SOUL Study)(2009. 4 ? present)
A Phase 2, Open-Label Pilot safety Study of JX594(Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus)Administered by Intravenous Infusion Followed by Intratumoral Injection Prior To standard Sorafenib treatment in patients with unresectable Primary Hepatocellular Carcinoma(2009.9 ? present)
A study to evaluate the efficacy and the change of sAg levels in chronic hepatitis B patients receiving Clevudine treatment over the long period(2010.1 ? present)
An Open-label, Randomized Phase 3 study of the Efficacy and Tolerability of Linifanib(ABT-869)versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma(HCC)(2010.4 ? present)
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2013 Aug 31. doi: 10.1136/gutjnl-2013-305138. [Epub ahead of print] PubMed PMID: 23979965.
Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B. Antivir Ther. 2013 Jul 31. doi: 10.3851/IMP2664. [Epub ahead of print] PubMed PMID: 23900457.
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. SciTransl Med. 2013 May 15;5(185):185ra63.
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013 Mar;19(3):329-36.
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 2013 Feb 15;73(4):1265-75.
A practical scoring system for predicting cirrhosis in patients with chronic viral hepatitis. Hepatogastroenterology. 2012 Nov-Dec;59(120):2592-7.
A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. Antivir Ther. 2012;17(8):1563-70.
A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012 Sep;107(9):1380-7.
Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2012 Jul;47(7):809-19.
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine. 2012 Mar 30;30(16):2689-96.
Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci. 2012 Jun;57(6):1682-91.
Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines. Korean J Hepatol. 2011 Sep;17(3):213-9.
Widespread cerebral cortical mineralization in Wilson's disease detected by susceptibility-weighted imaging. J Neurol Sci. 2012 Feb 15;313(1-2):54-6.
Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C. Clin Biochem. 2011 Dec;44(17-18):1396-9.
Somatostatin adjunctive therapy for non-variceal upper gastrointestinal rebleeding after endoscopic therapy. World J Gastroenterol. 2011 Aug 7;17(29):3441-7.
Usefulness of multiple biomarkers for the prediction of significant fibrosis in chronic hepatitis B. J Clin Gastroenterol. 2011
NoninvasivemarkerstodiagnosecirrhosisinpatientswithHBeAgpositivechronichepatitis:Donewbiomarkersimprovetheaccuracy?2010Jul;43(10-11):877-81.
PercutaneoustranshepaticcholedochoscopiclithotomyasarescuetherapyforremovalofbileductstonesinBillrothIIgastrectomypatientswhoaredifficulttoperformERCP.2009Dec;21(12):1358-62.
Qualitycontrolprobesforspot-uniformityandquantitativeanalysisofoligonucleotidearray.2009Jul;19(7):658-65.
[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection]. 2010Mar;16(1):38-48.
Clinicalfeaturesandprognosisofspontaneousbacterialperitonitisinkoreanpatientswithlivercirrhosis:amulticenterretrospectivestudy.2009Sep;3(3):197-204
Endoscopicremovalofabile-ductstoneusingsphincterotomyandalarge-balloondilatorinapatientwithsitusinversustotalis.2010Mar;4(1):110-3
The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection.KoreanJHepatol.2008Dec;14(4):503-12
Hepatic capsular and subcapsular pathologic conditions: demonstration with CT and MR imaging.Radiographics.2008;28(5):1307-23.Review
Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs.JKoreanMedSci.2008;23(3):521-5.
The efficacy and safety of telbivudine in korean patients with chronic hepatitis B]KoreanJHepatol.2007(4):503-12.
Lysophosphatidicacidinmalignantascitesstimulatesmigrationofhumanmesenchymalstemcells.JCellBiochem.2008May15;104(2):499-510.
Lysophosphatidic acid induces cell migration through the selective activation of Akt1. Exp Mol Med. 2008 Aug 31;40(4):445-52.
Clinicalfeaturesandtreatmentoutcomesofuppergastrointestinalbleedinginpatientswithcirrhosis.JKoreanMedSci.2008Aug;23(4):635-43.
Cancer-derivedlysophosphatidicacidstimulatesdifferentiationofhumanmesenchymalstemcellstomyofibroblast-likecells.StemCells.2008Mar;26(3):789-97.